[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[S. 1182 Introduced in Senate (IS)]
<DOC>
118th CONGRESS
1st Session
S. 1182
To amend the Public Health Service Act to increase the transparency and
accountability of the drug discount program, and for other purposes.
_______________________________________________________________________
IN THE SENATE OF THE UNITED STATES
April 18, 2023
Mr. Kennedy introduced the following bill; which was read twice and
referred to the Committee on Health, Education, Labor, and Pensions
_______________________________________________________________________
A BILL
To amend the Public Health Service Act to increase the transparency and
accountability of the drug discount program, and for other purposes.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``340B Reporting and Accountability
Act''.
SEC. 2. REQUIREMENT TO PROVIDE DRUG DISCOUNTS TO PATIENTS.
(a) In General.--Section 340B(a)(5) of the Public Health Service
Act (42 U.S.C. 256b(a)(5)) is amended--
(1) in subparagraph (C), by striking ``subparagraphs (A) or
(B)'' and inserting ``subparagraph (A), (B), or (E)'';
(2) in subparagraph (D), by striking ``subparagraphs (A) or
(B)'' and inserting ``subparagraph (A), (B), or (E)''; and
(3) by adding at the end the following:
``(E) Requirement to provide drug discounts to
patients.--A covered entity shall ensure that each
patient who receives a covered outpatient drug from
such covered entity is provided such drug at a price
that does not exceed the price at which the covered
entity purchased the drug in accordance with paragraph
(1), less any additional discounts or rebates received
by the covered entity with respect to the drug.''.
(b) Reporting Requirements for Drug Discount Program.--Section
340B(d)(2)(B) of the Public Health Service Act (42 U.S.C.
256b(d)(2)(B)) is amended by adding at the end the following:
``(vi)(I) Not later than 1 year after the
date of enactment of the 340B Reporting and
Accountability Act, the development of
procedures to require each covered entity to
report to the Secretary, not less frequently
than annually, information on--
``(aa) the total amount paid by the
covered entity during the reporting
period for covered outpatient drugs
under subsection (a);
``(bb) the total amount received by
the covered entity during the reporting
period for such covered outpatient
drugs; and
``(cc) if a covered entity receives
any revenue as a result of charging a
price for a covered outpatient drug
that exceeds the price at which the
covered entity purchased the drug, how
the covered entity spent such revenue.
``(II) The Secretary shall make the
information reported under subclause (I)
publicly available.''.
<all>